Abstract
The acquired immunodeficiency syndrome (AIDS) epidemic has had a profound impact on the community of injection drug users (IDUs) in the United States. The human immunodeficiency virus (HIV) is believed to have been introduced into this risk group in the mid-1970s,1,2 and within two decades estimates suggest that over 300,000 IDUs had become infected. During this time over 100,000 IDUs are believed to have died of AIDS-related causes. Injection drug use has become the leading cause of infection among newly diagnosed AIDS cases.3
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
Similar content being viewed by others
References
Des Jarlais DC, Friedman SR, Hopkins W. Risk reduction for the acquired immunodeficiency syndrome among intravenous drug users. Ann Intern Med 1985; 103:755–759.
Novick DM, Kreek MJ, Des Jarlais DC, et al. Abstract of clinical research findings: Therapeutic and historical aspects. NIDA Res Monogr 1985; 67:318–320.
Holmberg SD. Estimated prevalence and incidence of HIV in 96 large US metropolitan areas. Am J Public Health 1996; 86:642–654.
Cooper JR. Methadone treatment and acquired immunodeficiency syndrome. JAMA 1989; 262:1664–1668.
Vlahov D, Anthony JC, Celentano D, et al. Trends of HIV-1 risk reduction among initiates into intravenous drug use 1982–1987. Am J Drug Alcohol Abuse 1991; 17:39–48.
McCusker J, Stoddard A, Koblin B, et al. Time trends in high-risk injection practices in a multi-site study in Massachusetts: Effects of enrollment site and residence. AIDS Educ Prey 1992; 4:108–119.
Marmor M, Des Jarlais DC, Cohen H, et al. Risk factors for infection with human immunodeficiency virus among intravenous drug abusers in New York City. AIDS 1987; 1:39–44.
Koester S, Hoffer L. “Indirect sharing” additional risks associated with drug injection. AIDS Public Policy 1994; 2:100–105.
Institute of Medicine. Treating Drug Problems, vol. 1. Washington, DC: National Academy Press; 1990.
McLellan AT, Woody G, Metzger D, et al. Evaluating the effectiveness of addiction treatments: reasonable expectations, appropriate comparisons. Milbank Q 1996; 74:51–85.
Kozel NJ, Adams EH. Epidemiology of drug abuse: An overview. Science 1986; 234:970–974.
Hahn RA, Onorato I, Jones TS, Dougherty J. Prevalence of HIV infection among intravenous drug users in the United States. JAMA 1989; 261:2677–2684.
Battjes RJ, Pickens RW, Amsel Z. HIV infection and AIDS risk behaviors among intravenous drug users entering methadone treatment in selected US cities. J Acquir Immune Defic Syndr 1991; 4:1148–1154.
On MF, Glebatis D, Friedmann P, et al. Incidence of HIV infection in a New York City methadone maintenance treatment program. JAMA 1996; 276:99.
Hubbard RL, Marsden ME, Cavanaugh E, et al. Role of drug-abuse treatment in limiting the spread of AIDS. Rev Infect Dis 1988; 10:377–384.
McCusker J, Stoddard AM, Hindin RN, et al. Changes in HIV risk behavior following alternative residential programs of drug abuse treatment and AIDS education. Ann Epidemiol 1996; 6:119–125.
Ball JC, Lange RL, Myers CP, Friedman SR. Reducing the risk of AIDS through methadone maintenance treatment. J Health Soc Behav 1988; 29:214–226.
Ball JC, Ross A. The Effectiveness of Methadone Maintenance Treatment. New York: Springer-Verlag; 1991.
Booth RE, Crowley T, Zhang Y. Substance abuse treatment entry, retention and effectiveness: Out-of-treatment opiate injection drug users. Drug Alcohol Depend 1996; 42:11–20.
Center for Substance Abuse Treatment. NTIES: National Treatment Improvement Evaluation Study Preliminary Report: The Persistent Effects of Substance Abuse Treatment-One Year Later. Washington, DC: US Dept Health and Human Services; 1996.
Caplehorn JRM, Ross MW. Methadone maintenance and the likelihood of risky needle sharing. Int J Addic 1995; 30:685–698.
Abdul-Quader AS, Friedman SR, Des Jarlais DC, et al. Methadone maintenance and behaviors by intravenous drug users that can transmit HIV. Contemp Drug Prob 1987; 14:425–433.
Meandzija B, O’Connor P, Fitzgerald B, et al. HIV infection and cocaine use in methadone maintained and untreated injection drug users. Drug Alcohol Depend 1994; 36:109–113.
Avins AL, Woods WI, Lindan CP, et al. HIV infection and risk behaviors among heterosexuals in alcohol treatment programs. JAMA 1994; 271:515–518.
Shoptaw S, Frosch DL, Rawson RA, Ling W. Cocaine abuse counseling as HIV prevention. AIDS Educ Prey 1997; 9:509–518.
Calsyn DA, Sazon J, Freeman G, Whittaker S. Ineffectiveness of AIDS education and HIV antibody testing in reducing high-risk behaviors among injection drug users. Am J Public Health 1992; 82:573–575.
Booth RE, Watters JK. How effective are risk-reduction interventions targeting injecting drug users? AIDS 1994; 8:1515–1524.
Sorenson JL, Miller MS. Impact of HIV risk and infection on delivery of psychosocial treatment services in outpatient programs. J Subst Abuse Treat 1996; 13:387–395.
Selwyn PA. Impact of HIV infection on medical services in drug abuse treatment programs. J Subst Abuse Treat 1996; 13:397–410.
Centers for Disease Control and Prevention. Antibodies to a retrovirus etiologically associated with acquired immunodeficiency syndrome (AIDS) in populations with increased incidences of the syndrome. Morb Mortal Wkly Rep 1984; 33:377–379.
Brown LS, Burkette W, Primm BJ. Drug treatment and HIV seropositivity. NY State J Med 1988; 88:156.
Novick DM, Joseph H, Croxon TS, et al. Absence of antibody to human immunodeficiency virus in long-term, socially rehabilitated methadone maintenance patients. Arch Intern Med 1990; 150:97–99.
Blix O, Gronbladh L. Impact of methadone maintenance treatment on the spread of HIV among IV heroin addicts in Sweden. In: Loimer N, Schmid R, Springer A, eds. Drug Addiction and AIDS. New York: Springer-Verlag Wien; 1991:200–205.
Moss AR, Vranizan K, Goiter R, et al. HIV seroconversion in intravenous drug users in San Francisco, 19851990. AIDS 1994; 8:223–231.
Serpelloni G, Carriere MP, Rezza G, et al. Methadone treatment as a determinant of HIV risk reduction among injecting drug users: A nested case-controlled study. AIDS Care 1994; 6:215–220.
Metzger DS, Woody GE, McLellan AT, et al. Human immunodeficiency virus seroconversion among in-and outof-treatment intravenous drug users: An 18-month prospective follow-up. J Acquir Immune Defic Syndr 1993; 6:1049–1056.
Friedman SR, Jose B, Deren S, et al. Risk factors for HIV seroconversion among out-of-treatment drug injectors in high and low seroprevalence cities. Am J Epidemiol 1995; 142:864–874.
McLellan AT, Arndt IO, Metzger DS, et al. Effects of psychological services in substance abuse treatment. JAMA 1993; 269:1953–1959.
Yancovitz SR, Des Jarlais DC, Peskoe-Peyser N, et al. Randomized trial of an interim methadone maintenance clinic. Am J Public Health 1991; 81:1185–1191.
Etheridge RM, Craddock SG, Dunteman GH, Hubbard RL. Treatment services in two national studies of community-based drug abuse treatment programs. J Subst Abuse 1995; 7:9–26.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2000 Springer Science+Business Media New York
About this chapter
Cite this chapter
Metzger, D.S., Navaline, H., Woody, G.E. (2000). The Role of Drug Abuse Treatment in the Prevention of HIV Infection. In: Peterson, J.L., DiClemente, R.J. (eds) Handbook of HIV Prevention. Aids Prevention and Mental Health. Springer, Boston, MA. https://doi.org/10.1007/978-1-4615-4137-0_7
Download citation
DOI: https://doi.org/10.1007/978-1-4615-4137-0_7
Publisher Name: Springer, Boston, MA
Print ISBN: 978-1-4613-6855-7
Online ISBN: 978-1-4615-4137-0
eBook Packages: Springer Book Archive